FindTrial
Sign In

Effectiveness of Antidiabetic Treatment Applied in Childhood Obesity

The Effect of Anti-diabetic Treatment Applied in Childhood Obesity on Zinc, Zinc α-2 Glycoprotein and Peroxisome Proliferation Activating Receptor-γ Levels

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06266598
Enrollment
52
Registered
2024-02-20
Start date
2019-11-17
Completion date
2021-10-27
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Obesity, Insulin Resistance

Keywords

Obesity, Metformin, Biomarker

Brief summary

In our study, there are 33 healthy children with normal weight (control group) and 52 obese children who will be treated with metformin. To observe the efficacy of the 3-month treatment before and after metformin treatment, Zn, Zinc α-2 Glycoprotein (ZAG), Peroxisome proliferation activating receptor γ (PPARγ), Leptin (LEP) and Adiponectin (ADIPO) levels were compared, as well as anthropometric measurements and routine biochemistry tests.

Interventions

DRUGMetformin

Only obese children with insulin resistance were treated with metformin.

Sponsors

HÜMEYRA ACIKAN
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

In our study, there are 33 healthy children with normal weight (control group) and 52 obese children who will be treated with metformin. To observe the efficacy of the 3-month treatment before and after metformin treatment, Zn, Zinc α-2 Glycoprotein (ZAG), Peroxisome proliferation activating receptor γ (PPARγ), Leptin (LEP) and Adiponectin (ADIPO) levels were compared, as well as anthropometric measurements and routine biochemistry tests.

Eligibility

Sex/Gender
ALL
Age
9 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index (BMI) \> 95th percentile * Having insulin resistance * Having a family history of Type 2 diabetes mellitus (T2DM)

Exclusion criteria

; * Alcohol consumption and smoking * Having T1DM and T2DM * History of drug use

Design outcomes

Primary

MeasureTime frameDescription
Insulin resistance (HOMA-IR) levelthree monthsHOMA-IR is a condition in which the body's cells become less responsive to the effects of insulin. This means that the body needs more insulin to achieve the same effects, such as regulating blood sugar levels
Weight loss ratethree monthsWeight loss rate is typically defined as the amount of weight lost over a specific period of time.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026